XRTX
Xortx Therapeutics Inc
NASDAQ · Pharmaceuticals
$0.40
0.00 (-0.69%)
Income Statement
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 1.23M | 1.25M | 1.18M |
| Net Income | 271.6K | 338.7K | 243.7K |
| EPS | — | — | — |
| Profit Margin | 22.1% | 27.0% | 20.7% |
| Rev Growth | +6.1% | +20.7% | +12.6% |
Balance Sheet
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Total Debt | 2.56M | 2.36M | 2.22M |
| Total Equity | 3.69M | 3.65M | 3.81M |
| D/E Ratio | 0.69 | 0.65 | 0.58 |
Cash Flow
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| EBITDA | 408.7K | 499.5K | 428.0K |
| Free Cash Flow | 127.5K | 161.5K | 118.2K |